Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;60(5):2495-2506.
doi: 10.1007/s00394-020-02419-6. Epub 2020 Nov 7.

Glycemic control improvement in individuals with type 2 diabetes with vitamin K2 supplementation: a randomized controlled trial

Fatemeh Rahimi Sakak  1 , Nazanin Moslehi  2 , Mahtab Niroomand  3 , Parvin Mirmiran  4   5
Affiliations
Randomized Controlled Trial

Glycemic control improvement in individuals with type 2 diabetes with vitamin K2 supplementation: a randomized controlled trial

Fatemeh Rahimi Sakak et al. Eur J Nutr. 2021 Aug.

Abstract

Purpose: This study aimed to investigate the effects of vitamin K2 supplementation in the form of menaquinone-7 (MK-7) on glucose, insulin, and lipid metabolism in patients with type 2 diabetes mellitus (T2DM).

Methods: In this double-blinded, placebo-controlled, randomized trial, 68 insulin-independent people with diabetes received either 180 µg MK-7 twice a day or placebo for 12 weeks. We assessed fasting plasma glucose (FPG) and insulin concentrations (primary outcomes), glycated hemoglobin (HbA1c), insulin sensitivity indices, and lipid profiles (secondary outcomes) at baseline and end of the trial.

Results: At the end of the trial, FPG (effect size (ES) = - 0.68; p-adjusted = 0.031) and HbA1c (ES = - 0.36; p-adjusted = 0.004) were significantly lower in the vitamin K2 group compared with the placebo at the end of the trial. The number of participants achieved the target levels of glycemic control based on FPG, and HbA1c concentrations were significantly higher in the vitamin K2 group compared to the placebo group. Insulin concentrations (ES = - 0.29; p = 0.019) and homeostatic model assessment for insulin resistance (HOMA-IR) significantly decreased in the vitamin K2 group (ES = - 0.29; p = 0.019) compared to baseline, but their values were not significantly different compared to the placebo group at the end of the trial. No significant variation was observed in lipid profiles.

Conclusion: Daily intake of 360 µg Vitamin K2 in the form of MK-7 for 12-weeks reduces FPG and HbA1c in patients with T2DM but does not have a lipid-lowering effect.

Keywords: Diabetes mellitus; Glucose hemostasis; Insulin sensitivity; Randomized clinical trial; Vitamin K2.

PubMed Disclaimer

References

    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843 - DOI - PubMed
    1. Cavaiola TS, Pettus JH (2000) Management of type 2 diabetes: selecting amongst available pharmacological agents. In: Feingold KR, Anawalt B, Boyce A et al (eds) Endotext. MDText.com Inc, South Dartmouth (MA)
    1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in US diabetes care, 1999–2010. N Engl J Med 368(17):1613–1624. https://doi.org/10.1056/NEJMsa1213829 - DOI - PubMed
    1. Aldukhayel A (2017) Prevalence of diabetic nephropathy among Type 2 diabetic patients in some of the Arab countries. Int J Health Sci 11(1):1–4
    1. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615–1625. https://doi.org/10.2337/diabetes.54.6.1615 - DOI - PubMed

Publication types

LinkOut - more resources